Amgen (AMGN) DIvidends Date & History

Key Takeaways

• Amgen (AMGN) pays a quarterly dividend of $2.52 per share, an annualized payout of $10.08, with a recent dividend yield of roughly 2.3%.
• The company has raised its dividend for 15 consecutive years, positioning it as a dependable dividend growth stock rather than a high-yield name.
• Amgen's dividend is well covered by free cash flow, with cash-flow payout near 44%, supporting future increases.
• Dividend growth has compounded at about 9% annually over the past five years and roughly 12% annually over the past decade.
• Amgen's yield is modest compared with some high-yield pharmaceutical peers but attractive relative to growth-stage biotechs that pay no dividend.

Dividend Overview

Amgen Inc., a leading biotechnology company headquartered in Thousand Oaks, California, pays a quarterly cash dividend of $2.52 per share, which translates to an annualized payout of $10.08 per share. Based on recent share prices, this equates to a dividend yield of approximately 2.3%, modestly above the broad-market average. Dividends are typically declared and paid on a March, June, September, and December schedule, with the most recent ex-dividend date falling on August 21, 2026.

Rather than a high-yield income vehicle, Amgen is best characterized as a dividend growth stock. The company has steadily increased its quarterly payout each year, reflecting management's confidence in its cash generation and a commitment to returning capital to shareholders alongside share repurchases. This combination of a consistent payout and consistent growth makes Amgen appealing to investors seeking both income and long-term dividend appreciation.

Dividend History and Growth

Amgen has built a lengthy record of consistent dividend increases, now spanning 15 consecutive years. The quarterly dividend has climbed from $1.15 per share in 2017 to $2.52 per share today, while the annual payment has grown from roughly $3.16 per share in 2015 to $9.52 per share in the most recent full fiscal year — a compound annual growth rate (CAGR) of approximately 12% over that decade.

More recently, the company announced an increase from $2.38 to $2.52 per share in December 2025, effective with the February 2026 payment, representing a roughly 5.9% year-over-year raise. This steady, single-digit-to-double-digit cadence underscores Amgen's disciplined approach: prioritizing sustainable, moderate increases backed by earnings and cash flow rather than outsized one-time hikes. There have been no dividend cuts during this period, reinforcing the reliability of the payout.

Dividend Sustainability and Payout Ratio

Amgen's dividend appears well supported by its financial position. On a trailing earnings basis, the payout ratio sits in the low-60% range, though this metric can fluctuate with one-time charges. More importantly, the dividend consumes only about 44% of the company's free cash flow (FCF), leaving ample room for research and development, debt servicing, and continued buybacks. This free cash flow coverage is a key strength, because biotechnology earnings can be volatile due to acquisition-related amortization and milestone expenses.

Amgen maintains a strong balance sheet despite elevated debt following its acquisition of Horizon Therapeutics, with robust operating cash flow from a diversified portfolio of blockbuster drugs and a growing biosimilar business. The wide margin between cash generation and the dividend payment suggests the company can sustain — and likely continue growing — its payout even amid pipeline or patent-cycle pressures.

Dividend Compared to Industry Peers

Within the large-cap pharmaceutical and biotechnology sector, Amgen's roughly 2.3% yield is moderate. High-yield peers such as Pfizer (PFE) and Bristol-Myers Squibb (BMY) typically offer yields in the mid-single digits, while diversified giants like Johnson & Johnson (JNJ) yield around 3%. In contrast, many growth-focused biotechs — including Vertex Pharmaceuticals and Regeneron — pay no dividend at all.

Amgen therefore occupies a middle ground: it delivers a dependable, growing income stream that exceeds what investors receive from non-dividend-paying biotech innovators, yet trails the headline yields of more mature, slower-growing pharmaceutical names. For income-oriented investors, the trade-off is a somewhat lower current yield in exchange for stronger historical dividend growth and a substantial cash-flow cushion.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and exchange-traded funds (ETFs) with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is particularly useful for identifying dividend stocks, income-focused investments, trending names, breakout candidates, and emerging market opportunities more efficiently than manual screening. To explore tools for finding dividend-paying equities and other opportunities, visit the AI Screener.

Is This Stock Attractive for Dividend Investors?

Amgen may appeal most to dividend growth investors and long-term, total-return-oriented investors who prioritize steadily rising income over a high starting yield. Its 15-year streak of increases and roughly 9% five-year dividend growth rate make it a candidate for portfolios focused on compounding income over time. Income investors seeking maximum current yield may find more generous payouts elsewhere in the pharmaceutical space, while conservative investors can take some comfort in the dividend's strong free cash flow coverage.

However, the profile is not without considerations. Biotechnology carries patent-expiration and pipeline risks, and Amgen's elevated debt following recent acquisitions is worth monitoring. Investors who favor predictable, mature income streams may find the company suitable as a core holding, while those with shorter time horizons or a strict focus on the highest yields might look elsewhere. Ultimately, Amgen's dividend is best viewed as a balanced, growing income stream rather than a maximum-yield opportunity.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations